On October 27, 2026, Health Canada published its final Guidance for Clinical Trials with Decentralized Elements, providing regulatory direction for sponsors, investigators, and Contract Research Organizations (CROs) incorporating decentralized activities into clinical trials conducted in Canada. The guidance explains how existing requirements under Part C, Division 5 of the Food and Drug Regulations apply when trial activities are conducted outside traditional clinical research sites.
The guidance addresses decentralized approaches such as remote patient visits, electronic informed consent, digital health technologies, local health care providers, and investigational drug distribution. It also provides direction on clinical trial design, regulatory submissions, research ethics approvals, quality management, and oversight responsibilities.
Following a public consultation conducted between December 2025 and February 2026, Health Canada strengthened several areas of the guidance, particularly those concerning risk-based quality management, digital systems, investigational product handling, inspection readiness, and the delegation of trial-related responsibilities.
The publication does not introduce a separate regulatory framework or new legal requirements for decentralized clinical trials. Rather, it clarifies how existing regulatory obligations should be applied to increasingly flexible clinical research models.
For sponsors planning new studies or incorporating decentralized elements into ongoing trials, the guidance provides a more comprehensive reference for assessing regulatory requirements, identifying operational risks, and establishing appropriate oversight procedures while maintaining participant safety and data integrity.
Drug Clinical trials in Canada are regulated under the Food and Drugs Act and Part C, Division 5 of the Food and Drug Regulations, which establish requirements for clinical trial authorization, Good Clinical Practice (GCP), participant protection, investigational drug handling, and recordkeeping.
These requirements have traditionally been applied to studies conducted primarily at designated clinical research sites, where investigators oversee participant assessments, investigational treatments, and the collection of clinical data.
However, advances in digital health technologies, remote monitoring, and virtual health care have expanded the ways clinical research can be conducted. Decentralized approaches allow certain activities to occur closer to participants, potentially reducing geographic and logistical barriers while improving recruitment, retention, and access to clinical trials.
Recognizing these developments, Health Canada released draft guidance on December 23, 2025, to clarify how existing regulatory requirements apply to clinical trials incorporating decentralized elements.
The consultation period concluded on February 21, 2026, with Health Canada receiving 35 submissions from stakeholders, including clinical trial sponsors, investigators, CROs, technology providers, research ethics boards, academic researchers, and patient advocacy organizations.
Following its review of stakeholder feedback, Health Canada published the final guidance on October 27, 2026.
The publication also forms part of Health Canada’s broader initiative to modernize Canada’s clinical trial regulatory framework. While the current guidance operates under existing regulations and applicable interim policies, Health Canada anticipates further revisions following the implementation of its proposed modernized Clinical Trials Regulations.
Health Canada’s Guidance for Clinical Trials with Decentralized Elements applies to Phase I through Phase IV clinical trials involving pharmaceuticals, biologics, and radiopharmaceuticals for human use in Canada.
The guidance is intended for organizations involved in designing, sponsoring, conducting, or supporting these studies, including pharmaceutical manufacturers, clinical investigators, CROs, health care providers, clinical laboratories, and technology service providers.
Although similar principles may be relevant to other types of clinical research, the guidance does not directly apply to clinical investigations involving medical devices, Natural Health Products (NHPs), or foods for special dietary purposes, which are regulated under different frameworks.
Health Canada describes clinical trials with decentralized elements as studies in which some or all trial-related activities occur outside traditional clinical trial centres. These studies may incorporate remote, virtual, or home-based activities while maintaining oversight through an established clinical trial site.
Decentralized elements may include:
The guidance accommodates both fully decentralized and hybrid clinical trial models, allowing sponsors to determine which activities can appropriately be conducted remotely based on the investigational product, study objectives, participant population, and associated risks.
However, the inclusion of decentralized elements does not change the underlying regulatory obligations. Sponsors must continue to demonstrate that clinical trials are scientifically sound, appropriately supervised, and conducted in accordance with GCP requirements.
The principal consideration is whether the proposed decentralized activities can be implemented without compromising participant safety, the reliability of clinical data, or regulatory compliance.
The October 2026 guidance consolidates regulatory considerations that previously required interpretation across existing clinical trial regulations, GCP guidance, and related policies.
Health Canada’s revisions following public consultation place greater emphasis on the practical implementation of decentralized activities, particularly where responsibilities, clinical data, and investigational products are distributed across multiple locations.
The following table summarizes the principal areas addressed in the finalized guidance and their implications for clinical trial sponsors.
| Regulatory Area | Guidance and Practical Implications |
| Trial design and risk management | Establishes considerations for incorporating decentralized activities into protocols while identifying critical-to-quality factors and implementing proportionate risk controls. |
| Clinical trial sites | Clarifies how remote locations can operate under the oversight of a qualified investigator without necessarily requiring separate clinical trial site registrations. |
| Digital technologies | Provides direction on computerized systems, data integrity, cybersecurity, validation, and the appropriate use of remote monitoring technologies. |
| Regulatory submissions | Explains when adding decentralized elements to an authorized trial may require a Clinical Trial Application Amendment (CTA-A), notification (CTA-N), or neither. |
| Informed consent | Addresses electronic and remote consent processes, participant communication, documentation, and applicable ethical requirements. |
| Investigational products | Clarifies considerations for transporting, storing, dispensing, and maintaining accountability for investigational drugs across decentralized locations. |
| Oversight and delegation | Reinforces sponsor and qualified investigator responsibilities when activities are delegated to local health care providers, CROs, and other service providers. |
| Regulatory inspections | Provides direction on maintaining accessible records and demonstrating appropriate oversight of activities conducted outside traditional trial sites. |
Source: Health Canada’s October 2026 guidance and accompanying publication notice.
The most significant development is the availability of consolidated regulatory direction addressing how these activities can be implemented within Canada’s existing clinical trial framework.
The finalized guidance emphasizes that decentralized elements should be considered during protocol development and incorporated into the study’s overall quality management strategy.
Sponsors are expected to evaluate whether decentralized procedures are appropriate for the investigational product, participant population, and intended clinical assessments. This includes identifying potential risks to participant safety, protocol compliance, and the accuracy or completeness of clinical data.
Health Canada places particular emphasis on critical-to-quality factors, which are aspects of trial design and conduct that could meaningfully affect participant rights, safety, well-being, or the reliability of study results.
For example, a clinical trial using remote monitoring technologies may need additional procedures to address missing data, device malfunctions, inconsistent assessments, or delayed communication of clinically significant findings.
Similarly, studies involving home-based drug administration may require additional safeguards concerning medical supervision, personnel qualifications, and emergency response procedures.
Rather than requiring identical controls for every decentralized activity, the guidance supports a risk-proportionate approach consistent with ICH E6(R3) and Health Canada’s GCP requirements.
Sponsors should therefore establish documented procedures that address the specific risks associated with their proposed trial design.
Decentralized clinical trials introduce additional considerations concerning the definition of a clinical trial site and the responsibilities of the qualified investigator (QI).
Health Canada’s guidance clarifies that activities conducted at remote locations may remain under the oversight of a single clinical trial site and its designated QI.
Health Canada does not require separate Clinical Trial Site Information (CTSI) forms or REB approvals for remote locations where decentralized activities are conducted under the QI’s oversight and according to the approved protocol. However, additional provincial, institutional or community-specific approvals or permissions may still be required.This distinction can provide operational flexibility for studies incorporating local laboratories, community health care providers, or home-based assessments.
However, the QI remains accountable for the conduct of trial activities under their supervision, including participant safety, investigational product accountability, data integrity, and compliance with applicable requirements.
The guidance also reflects Health Canada’s September 2026 interim modernization policy, which permits a broader range of appropriately qualified researchers to serve as QIs. Where the QI is not a physician or dentist, trial-related medical decisions must remain under the responsibility of an appropriately licensed physician or dentist on the clinical trial team.
Sponsors should ensure that responsibilities, delegation arrangements, communication procedures, and oversight mechanisms are clearly established before decentralized activities begin.
Digital technologies are central to many decentralized clinical trial models, particularly where participant assessments, data collection, and communications occur remotely.
The finalized guidance provides additional direction concerning the selection, validation, security, and ongoing oversight of computerized systems used to support these activities.
Sponsors should ensure that digital technologies are appropriate for their intended purpose and capable of generating reliable clinical data. Depending on the system, this may involve evaluating data transmission, cybersecurity, access controls, audit trails, interoperability, and procedures for managing technical failures.
The guidance also addresses the use of artificial intelligence and algorithmic technologies, emphasizing the importance of evaluating their reliability, transparency, performance, and continued suitability throughout the trial.
Electronic informed consent is another area where decentralized approaches may provide additional flexibility.
Health Canada’s September 2026 interim policy permits appropriately documented consent processes that are not limited to traditional written signatures, including electronic platforms and other formats consistent with applicable laws and GCP requirements.
However, sponsors must still ensure that participants receive sufficient information, understand the risks and anticipated benefits, and have appropriate opportunities to ask questions before agreeing to participate.
The guidance also emphasizes accessibility, recognizing that digital technologies can create barriers for participants with limited internet access, disabilities, language barriers, or low digital literacy.
Accordingly, sponsors should consider participant-centred approaches, including alternative consent methods and appropriate technical support where necessary.
Decentralized clinical trials may involve investigational drugs being transported, stored, dispensed, or administered at locations outside conventional research sites.
Although these arrangements can improve participant accessibility, they introduce additional logistical and quality considerations.
Health Canada’s guidance explains that sponsors and investigators remain responsible for ensuring investigational products are handled according to applicable regulatory requirements and the approved protocol.
This includes maintaining appropriate storage conditions, product accountability, traceability, and procedures for identifying and addressing transportation or handling deviations.
For example, an investigational product requiring temperature-controlled storage may require documented transportation procedures and monitoring arrangements to demonstrate that its required conditions are maintained throughout distribution.
Sponsors must also consider applicable provincial and territorial requirements, particularly where investigational products are shipped directly to participants or dispensed through local pharmacies.
The use of decentralized distribution arrangements therefore requires appropriate planning and coordination between sponsors, investigators, pharmacies, logistics providers, and other delegated parties.
The finalized guidance reinforces that delegating trial-related activities does not transfer the sponsor’s overall responsibility for ensuring regulatory compliance.
Sponsors must maintain appropriate oversight of CROs, technology vendors, health care providers, and other third parties involved in decentralized trial activities.
Similarly, qualified investigators remain responsible for the activities conducted under their supervision, even when those activities occur at remote locations.
This requires clearly defined responsibilities, appropriate training, documented delegation arrangements, and procedures for monitoring performance and addressing deviations.
These arrangements should distinguish trial-specific activities from routine clinical procedures. Routine blood tests, medical imaging and standard-of-care procedures generally do not require trial-specific training or formal delegation by the QI, although appropriate qualifications should be confirmed where feasible.
Health Canada also provides additional direction concerning regulatory inspections.
Although the main clinical trial site generally remains the primary point of contact, inspectors may request documentation demonstrating appropriate oversight of decentralized activities and may inspect other locations where study-specific procedures were performed.
Records relating to remote activities must therefore remain accessible and sufficiently complete to demonstrate compliance with the protocol and applicable regulatory requirements.
For sponsors, inspection readiness should be incorporated into the operational design of decentralized trials rather than addressed only when an inspection is anticipated.
The October 2026 guidance does not replace the existing regulatory framework governing clinical trials in Canada.
Instead, it explains how established requirements under Part C, Division 5 of the Food and Drug Regulations apply when sponsors incorporate decentralized elements into their studies.
This distinction is particularly relevant to clinical trial authorization and post-authorization changes.
Under the existing framework, sponsors conducting applicable Phase I through Phase III drug trials must submit a Clinical Trial Application (CTA) to Health Canada before commencing the study.
Where decentralized activities are planned, the CTA and supporting documentation should describe the proposed arrangements sufficiently to demonstrate that participant safety, trial oversight, and study objectives will be appropriately maintained.
For previously authorized trials, the regulatory requirements depend on whether introducing decentralized elements changes the approved protocol and whether those changes meet the criteria for an amendment.
Health Canada’s guidance on regulatory and ethics approval identifies three principal scenarios:
| Scenario | Regulatory Requirement |
| Decentralized activities require protocol changes affecting participant safety, efficacy evaluation, safety evaluation, or other criteria under C.05.008. | A CTA-A must generally be submitted and authorized before implementation. Where an immediate amendment is necessary because the trial or use of the drug endangers the health of participants or others, it may be implemented immediately, with notification and submission of a CTA-A to Health Canada within 15 calendar days. |
| Decentralized activities require protocol changes that do not meet the criteria for a CTA-A. | A CTA-N is required. Qualifying changes may be implemented immediately, with written notification submitted within 15 calendar days. |
| Decentralized activities do not require changes to the approved protocol. | A CTA-A or CTA-N is generally not required, provided the activities remain compliant with the protocol and applicable GCP requirements. |
This clarification is particularly relevant for sponsors considering decentralized procedures after a study has already commenced.
For example, replacing certain in-person follow-up assessments with remote visits may require different regulatory actions depending on whether the change affects participant monitoring, study endpoints, safety evaluations, or other protocol requirements.
Sponsors should therefore evaluate proposed modifications against the applicable amendment and notification criteria rather than assuming that all decentralized changes require additional authorization.
The guidance also encourages sponsors to consider potential decentralized arrangements during initial protocol development, which may reduce the need for subsequent amendments when operational circumstances change.
The finalized guidance provides an opportunity for sponsors and CROs to review their existing clinical trial procedures and determine whether additional measures are needed to support decentralized activities.
For organizations planning new studies, this review should begin during protocol development and regulatory strategy planning.
Sponsors should assess which trial procedures can appropriately be conducted remotely, whether the proposed arrangements introduce additional participant safety or data integrity risks, and how those risks will be managed.
For ongoing studies, organizations should evaluate whether existing decentralized activities are adequately addressed in their protocols, quality management systems, and oversight procedures.
Particular attention should be given to the following areas:
Protocol and regulatory assessment: Review proposed decentralized activities against the approved protocol and determine whether additional regulatory submissions or research ethics approvals are necessary.
Risk management: Identify critical-to-quality factors and establish proportionate controls addressing participant safety, clinical assessments, investigational product handling, and data reliability.
Technology and data management: Evaluate digital systems for suitability, validation, cybersecurity, accessibility, and appropriate management of clinical trial data.
Delegation and oversight: Confirm that responsibilities assigned to investigators, CROs, local health care providers, and technology vendors are clearly documented and supported by appropriate qualifications and training.
Inspection readiness: Ensure that trial records, delegation documentation, monitoring reports, and investigational product accountability information remain complete and accessible.
Sponsors should also consider how decentralized approaches may affect participant experience, including accessibility, communication, and continuity of care.
A structured gap assessment can help identify areas where existing procedures require clarification or additional safeguards before decentralized activities are implemented.
Health Canada’s decentralized clinical trial guidance is part of a broader effort to modernize the Canadian clinical research environment.
The proposed regulatory modernization initiative is intended to accommodate evolving clinical trial designs while maintaining appropriate safeguards for participants and the integrity of research data.
According to Health Canada’s October 2026 announcement, the final version of the modernized Clinical Trials Regulations is expected to be published in the Canada Gazette, Part II, in spring 2027, followed by a one-year coming-into-force period.
Health Canada has indicated that the decentralized clinical trial guidance will be updated again to reflect the modernized regulatory framework once the new regulations take effect.
Sponsors should therefore distinguish between the requirements currently applicable to decentralized trials and potential future regulatory changes.
Organizations developing longer-term clinical research programs may benefit from monitoring the clinical trials modernization initiative and incorporating regulatory flexibility into their development strategies.
The October 2026 guidance provides a practical foundation for implementing decentralized approaches under the current framework while preparing for the continued evolution of clinical trial regulation in Canada.
dicentra provides regulatory consulting and full-service clinical research support to pharmaceutical and life sciences companies conducting clinical trials in Canada and the United States.
Our clinical research and regulatory teams support sponsors throughout the clinical development process, from initial regulatory strategy and protocol development through clinical trial authorization, study execution, monitoring, and regulatory compliance.
For sponsors considering decentralized clinical trial approaches, dicentra can assist with evaluating study design, identifying regulatory requirements, and determining whether proposed activities can be appropriately incorporated into an existing or planned clinical trial.
Our regulatory affairs team supports the preparation and submission of Clinical Trial Applications (CTAs), Clinical Trial Application Amendments (CTA-As), and applicable regulatory notifications, while our clinical research team provides operational support for study implementation, investigator coordination, monitoring, and quality management.
We also assist sponsors in evaluating GCP compliance, oversight responsibilities, and documentation requirements to help ensure that decentralized trial activities are conducted in accordance with applicable Canadian regulations and Health Canada guidance.
As decentralized approaches become increasingly integrated into clinical research, establishing an appropriate regulatory and operational strategy early in development can help sponsors identify potential challenges, reduce unnecessary administrative burden, and maintain the quality and reliability of clinical trial results.
Whether you are planning a new clinical trial, incorporating remote activities into an existing study, or assessing compliance with Health Canada’s finalized guidance, dicentra can help develop a regulatory and clinical strategy tailored to your study objectives.
For assistance with clinical trial regulatory requirements, study design, or clinical research services in Canada, contact dicentra’s regulatory affairs and clinical research team.
Our experts can help evaluate your clinical development program, identify applicable Health Canada requirements, and determine an appropriate approach to incorporating decentralized elements into your study.
Contact dicentra to discuss your clinical trial requirements and learn how our regulatory and clinical research services can support your development program.